Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital

Contributed by: Business Wire

Logo

Images

Rubedo Life Sciences scientists. Photo credit: ALESSANDRO GANDOLFI

Business Wire embedded0

Tags

Biotechnology

Other Health

Health

Pharmaceutical

Oncology

Other Science

Research

Infectious Diseases

Genetics

Science

Clinical Trials

Series A Financing

More Like This

Marco Quarta (right), Rubedo Life Sciences CEO and Co-Founder, notarizes the incorporation of Rubedo's European Headquarters in Milan (Photo: Business Wire)

Rubedo Life Sciences Announces European Expansion Ahead of First Clinical Trial

Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging

Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496, the First GPX4 Modulator Targeting Pathologic Senescent Cells To Enter Phase 1 Clinical Trial

Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board

Rubedo Life Sciences scientists (Photo: Business Wire)

Rubedo Life Sciences and Beiersdorf Announce Multi-Year Partnership to Pioneer New Skin Care Products that Address Cellular Aging

Image created by Clara Leibenguth for Stanford University; featured on cover of May 2025 issue of Nature Neuroscience.

Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience

Beacon Therapeutics Announces Closing of Oversubscribed Series C Financing for Over $75 Million

Almirall Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology at J.P. Morgan Healthcare Conference